Blood Res 2019; 54(1): 77-79  https://doi.org/10.5045/br.2019.54.1.77
Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
Jun Ho Yi1, Hye Ryoun Kim2
1Division of Hematology-Oncology, Department of Medicine, 2Department of Laboratory Medicine, Chung-Ang University, Seoul, Korea
Correspondence to: Jun Ho Yi, Division of Hematology-Oncology, Department of Medicine, Chung-Ang University, Heuksuk-ro 102, Dongjak-gu, Seoul 06973, Korea, E-mail: xuno@cau.ac.kr
Received: July 10, 2018; Revised: October 18, 2018; Accepted: October 29, 2018; Published online: March 31, 2019.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


e-submission

This Article

Current Issue

ba_link01

Indexed/Covered by

Today : 12  /
Total : 135,617